| Outcome Measures: |
Primary: Maximum plasma concentration (Cmax) of ertugliflozin for the Single Dose Cohort, Up to Day 4 of each treatment period|Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin for the Single Dose Cohort, Up to Day 4 of each treatment period|Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin for the Single Dose Cohort, Up to Day 4 of each treatment period|AUC from Hour 0 to infinity (AUCinf) for ertugliflozin for the Single Dose Cohort, Up to Day 4 of each treatment period|Ertugliflozin half life (t1/2) for the Single Dose Cohort, Up to Day 4 of each treatment period|Apparent clearance (CL/F) of ertugliflozin for the Single Dose Cohort, Up to Day 4 of each treatment period|Apparent volume of distribution (Vz/F) for the Single Dose Cohort, Up to Day 4 of each treatment period|Accumulation Ratio of Area Under the Curve for the dosing interval of ertugliflozin (Rac) for the Single Dose Cohort, Up to Day 4 of each treatment period|Number of participants who experienced an adverse event (AE) for the Single Dose Cohort, Up to 10 days after the final dose of study drug (Up to Day 11)|Number of participants who discontinued study drug due to an AE for the Single Dose Cohort, Up to Day 1 of each treatment period|Urinary Glucose Excretion over 24 hours for the Single Dose Cohort, Up to 24 hours postdose (Up to Day 2)|Cmax of ertugliflozin for the Multiple Dose Cohort, Up to Day 10|Tmax of ertugliflozin for the Multiple Dose Cohort, Up to Day 10|AUClast for ertugliflozin for the Multiple Dose Cohort, Up to Day 10|AUCinf for ertugliflozin for the Multiple Dose Cohort, Up to Day 10|t1/2 for the Multiple Dose Cohort, Up to Day 10|CL/F of ertugliflozin for the Multiple Dose Cohort, Up to Day 10|Vz/F for the Multiple Dose Cohort, Up to Day 10|Rac for the Single Dose Cohort, Up to Day 10|Number of participants who experienced an AE for the Multiple Dose Cohort, Up to 10 days after the final dose of study drug (Up to Day 17)|Number of participants who discontinued study drug due to an AE for the Multiple Dose Cohort, Up to Day 7|Urinary Glucose Excretion over 24 hours for the Multiple Dose Cohort, Up to 24 hours postdose (Up to Day 8) |
|
